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Abstract
Background: The polypeptides involved in amyloidogenesis may be globular proteins with a
defined 3D-structure or natively unfolded proteins. The first class includes polypeptides such as β2-
microglobulin, lysozyme, transthyretin or the prion protein, whereas β-amyloid peptide, amylin or
α-synuclein all belong to the second class. Recent studies suggest that specific regions in the
proteins act as "hot spots" driving aggregation. This should be especially relevant for natively
unfolded proteins or unfolded states of globular proteins as they lack significant secondary and
tertiary structure and specific intra-chain interactions that can mask these aggregation-prone
regions. Prediction of such sequence stretches is important since they are potential therapeutic
targets.
Results: In this study we exploited the experimental data obtained in an in vivo system using β-
amyloid peptide as a model to derive the individual aggregation propensities of natural amino acids.
These data are used to generate aggregation profiles for different disease-related polypeptides. The
approach detects the presence of "hot spots" which have been already validated experimentally in
the literature and provides insights into the effect of disease-linked mutations in these polypeptides.
Conclusion: The proposed method might become a useful tool for the future development of
sequence-targeted anti-aggregation pharmaceuticals.
Background
In the last decade, protein aggregation has moved beyond
being a mostly ignored area of protein chemistry to
become a key topic in medical sciences [1], mainly
because the presence of insoluble deposits in human tis-
sues correlates with the development of many debilitating
human disorders including the amyloidoses and several
neurodegenerative diseases [2]. The proteins involved in
these diseases are not related in terms of sequence or sec-
ondary structure content. From the conformational point
of view, two major classes can be distinguished: globular
proteins with a stable unique conformation in the native
state and intrinsically unstructured proteins [3]. Globular
proteins rarely aggregate from their native states and
destabilization, resulting in an increased population of
unfolded molecules, is well established as a trigging factor
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that are globular in their normal functional states [4], as
in the cases of β2-microglobulin, lysozyme, transthyretin
and the prion protein. Interestingly enough, many pro-
teins involved in depositional disorders are mostly
unstructured within the cell [3]. These include amylin,
amyloid-β-protein, and α-synuclein, among others. In
these cases, protein deposition does not require unfolding
and can occur by direct self-assembly of the unstructured
polypeptide chains.
One of the major unanswered questions of protein aggre-
gation is the specificity with which the primary sequence
determines the aggregation propensity from totally or par-
tially unfolded states. Deciphering the answer to this
question will give us a chance to control the unwanted
protein deposition events through specific sequence-tar-
geted therapeutics. A first advance in this direction is the
recent discovery that not all regions of a polypeptide are
equally important for determining its aggregation ten-
dency, both in natively unfolded and globular proteins. In
this way, some authors, including ourselves, have proved
recently that very short specific amino acid stretches can
act as facilitators or inhibitors of amyloid fibril formation
[5,6]. These relevant regions are usually known as aggre-
gation "hot spots". Aggregation-prone regions are likely to
be blocked in the native state of globular proteins because
their side chains are usually hidden in the inner hydro-
phobic core or already involved in the network of contacts
that stabilizes a protein. This accounts for the protective
role of the native structure against aggregation [7]. In con-
trast, aggregation-prone regions are already exposed to
solvent in natively unfolded proteins, available for the
establishment of inter-molecular contacts that may finally
lead to the formation of aggregates. Accordingly, the pres-
ence of putative "hot spots" of aggregation is much more
frequent in the sequences of globular proteins than in
those coding for natively unfolded proteins [8]. The pres-
ence of aggregation-prone regions has been described in
most of the peptides and proteins underlying neurode-
generative and systemic amyloidogenic disorders [9].
We have used a simple in vivo system to study the aggrega-
tion effects of a complete set of mutations in one of the
best characterized "hot spots" in a disease-linked protein:
the central hydrophobic cluster (CHC) of the Amyloid-β-
protein (Aβ) [10,11]. The results in this and other studies
on protein models not related to disease [12], suggested
that common and simple principles underlie protein
aggregation, at least from totally or partially unfolded
states, and that the propensities of proteins backbones to
aggregate are sharply modulated by the sequences that
dress them. Based on these assumptions, we have devel-
oped a simple approach that identifies the presence of
"hot-spots" of aggregation in globular and unstructured
disease-linked polypeptides and predicts the aggregation
effects of mutations in their sequences.
Results and discussion
Aggregation propensities of natural amino acids
The rationale behind our study is based on two recent
observations in the field. First, not all the polypeptide
sequence is relevant for the aggregation of a given protein,
but rather there exist specific regions that drive the process
[5,6] and second, similar simple rules appear to underlie
the aggregation propensities of unrelated proteins from
unfolded states [12]. According to these two assumptions
one may expect that the conclusions obtained from the
study of a relevant "hot spot" of aggregation in a specific
protein could apply to other unrelated proteins involved
in disease. As commented upon previously, we have
exploited an in vivo reporter method to calculate the rela-
tive aggregation propensities of each individual natural
amino acid when placed in the central position of the
CHC of Aβ (see Material and Methods). The highest aggre-
gation propensities correspond to isoleucine, phenyla-
lanine, valine, and leucine, whereas aspartic, glutamic,
asparagine, and arginine exhibit the lowest (Table 1). In
general, hydrophobic residues tend to induce aggregation
whereas polar ones promote solubility, matching the gen-
eral assumption that hydrophobic interactions are sup-
posed to play an important role in protein aggregation
[13].
Table 1: Relative experimental aggregation propensities of the 
20 natural amino acids derived from the analysis of mutants in 
the central position of the CHC in amyloid-β-protein.
Amino acid
I 1.822
F 1.754
V 1.594
L 1.380
Y 1.159
W 1.037
M 0.910
C 0.604
A -0.036
T -0.159
S -0.294
P -0.334
G -0.535
K -0.931
H -1.033
Q -1.231
R -1.240
N -1.302
E -1.412
D -1.836Page 2 of 15
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of the effects of protein mutation on the aggregation 
propensity
Provided that a given polypeptide aggregates from an at
least partially unstructured state, the experimental intrin-
sic aggregation propensities shown in Table 1 should
apply independently of the protein context. Thus, a pro-
file can be theoretically generated for any protein
sequence to detect those regions with aggregation propen-
sities above the average value of the whole sequence. This
leads directly to the definition of "hot spot" of aggregation
as a certain region that displays higher aggregation pro-
pensity than the rest of the sequence. Interestingly, a
related approach has been reported very recently for the
analysis of unstructured proteins associated with neuro-
degenerative diseases[14].
A good number of natural occurring mutations have been
reported in proteins associated to depositional diseases.
In many cases they result in changes in the global protein
aggregation propensity and sometimes in the appearance
of premature or acute pathological symptoms. The change
in average aggregation propensity (∆AP) between the wild
type and the different mutants should predict the effect of
sequence variations on the aggregation propensities, pro-
vided that they rely on changes in the intrinsic polypep-
tide properties.
Analysis of disease-related polypeptide sequences
In this section the above described analysis is applied to a
set of proteins linked to depositional diseases and the
obtained results are compared with the available experi-
mental data.
Intrinsically unstructured proteins
Amyloid-β-protein
As a proof of principle our approach was first tested in the
molecule from which the experimental amino acid aggre-
gation propensities were derived. Alzheimer's disease
(AD) is a progressive neurodegenerative disorder charac-
terized by the patient's memory loss and impairment of
cognitive abilities. The extracellular amyloid is found in
the brain and is widely believed to be involved in the pro-
gression of the disease [15]. The principal component of
the lesions is the hydrophobic polypeptide Aβ. The most
abundant forms found in amyloid plaques are a 40-mer
(Aβ40) and a 42-mer (Aβ42). Although less abundant,
Aβ42 is more amyloidogenic than Aβ40 and is the major
component of neuritic plaques [16]. Two main regions
with high aggregation propensity can be distinguished in
the aggregation profile for this polypeptide (Fig. 1). The
second region arises from the contribution of two
sequence stretches comprising residues 30–36 and 38–42,
respectively. The predicted aggregation-prone regions are
in excellent agreement with the experimental data in the
literature. Residues 16–21 overlap with the CHC sequence
comprising residues 17–21, a particular region recognized
to play a key role in Aβ aggregation and that is defined as
specially relevant for the amyloidogenesis of the Aβ40 and
Aβ42 peptides by two recent proline-scanning-mutagene-
sis studies [17,18]. In addition, structural studies using
solid state-NMR [19] and site-directed spin labeling [20]
have revealed that residues 16–21 are located in the core
of Aβ fibrils. Accordingly, a short 7 residues fragment
comprising residues 16–22 is able to form ordered amy-
loid fibrils [21] and, more interestingly, 16-LVAFF-20 and
derived peptides have been shown to bind to Aβ42 and
act as potent inhibitors of amyloid formation [22]. The
region 30–42, including both 30–36 and 38–42 stretches,
has been also implicated in Aβ aggregation. Proline-scan-
ning-mutagenesis revealed that the region 31–36 is sensi-
tive to proline replacement and likely to include a β-sheet
portion of the Aβ fibrils [17,18]. The contribution of the
C-terminal region 38–42 to Aβ amyloidogenesis becomes
clear from the observation that, although Aβ40 is pro-
duced in greater abundance in vivo, the prevalence of the
full-length 42-mer in plaques is much higher [16]. Exper-
iments with truncated synthetic Aβ peptides have con-
firmed that Aβ39 and Aβ40 are kinetically soluble for
several days, whereas Aβ42 immediately aggregates into
amyloid fibrils [23]. The relevance of the predicted 30–42
region is confirmed by structural studies that demonstrate
that residues 30–40 are located in the core of the Aβ fibrils
[20].
A set of mutations in the CHC and adjacent positions of
Aβ42 is intimately associated to early-onset familial
Alzheimer diseases (FAD). The substitutions include
A21G (Flemish), E22Q (Dutch) and E22G (Arctic) [24].
Aβ42 congeners bearing these mutations display distinct
aggregation kinetics. The rate of fibril formation by the
Flemish mutant is decreased relative to WT Aβ42, whereas
the Dutch mutant peptide aggregates substantially faster.
The Arctic peptide does not shows an overall change in the
rate of fibrillogenesis relative to WT Aβ42, but rather
accelerated protofibril formation. To assess whether the
effect of such mutations could be predicted by the present
approach we calculated ∆AP for the different sequences.
The results obtained describe accurately the effects docu-
mented in the literature (Table 2).
Adding to the mutations present in the population, a large
set of mutations has been artificially introduced on Aβ
that result in changes in its aggregation propensity. ∆AP
values were also calculated for several of them and the
results compared with the experimental data (Table 2).
The calculated changes in aggregation propensity are in
excellent agreement with the trends reported in the litera-
ture. Briefly, we predict the changes in aggregation of F19
mutants, those of I31 and I32 in the 30–36 region andPage 3 of 15
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BMC Structural Biology 2005, 5:18 http://www.biomedcentral.com/1472-6807/5/18Aggregation profile of natively unfolded proteins related to disease.Figure 1
Aggregation profile of natively unfolded proteins related to disease. The average aggregation propensity of the differ-
ent polypeptides is shown as a dashed line. Minimal protein regions which have been experimentally proven to be involved in 
aggregation are shown at the top of the plot as black bars. Regions in the core of the fibrils are shown as grey bars (when infor-
mation available). The NAC fragment of α-Synuclein is shown as a dashed bar.
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the effects of deletions both in the N and the C ends.
Finally, we also predict the high solubility of Aβ versions
generated by random mutagenesis [25].
Islet amyloid polypeptide
Type II diabetes is associated with progressive beta-cell
failure manifested as a decline in insulin secretion and
increasing hyperglycemia. A growing body of evidence
suggests that beta-cell failure in type II diabetes correlates
with the formation of pancreatic islet amyloid. Islet amy-
loid polypeptide (IAPP, amylin), the major component of
islet amyloid, is co-secreted with insulin from beta-cells.
In type II diabetes, this peptide aggregates to form amy-
loid fibrils that are toxic to beta-cells [26]. IAPP is an
unstructured peptide hormone of 37 amino acid residues.
Two "hot spots" of aggregation comprising residues 12–
18 and 22–28 are detected for this peptide (Fig. 1). Inter-
estingly enough, a 8–37 IAPP-fragment including both
"hot spots", has been shown to form amyloid fibrils under
physiological conditions [27]. The two aggregation prone
regions sharply coincide with those protected in the core
of the fibrils in a recently described structural model of
IAPP aggregates [28]. In this study, residues 12–17 and
22–27 are proposed to form the inner β-sheets in the fibril
protofilament structure. According to this hypothesis,
peptides corresponding to residues 8–20, 10–19, 20–29
of human IAPP, which include one of the "hot spots"
described here, all form amyloid [29-31]. Smaller pep-
tides derived from these regions have also been shown to
form amyloid, and a recent investigation suggests that the
minimal amyloid forming fragment of IAPP consists of
residues 22–27. This hexapeptide fragment, NFGAIL,
forms β-sheet-containing fibrils that coil around each
other in typical amyloid fibril morphology [32].
The analysis also explains the available mutational data
on IAPP. Diabetes-associated IAPP amyloid occurs in pri-
mates and cats but not in rodents [33]. Consistently, the
sequences of peptides 20–29 of rodents display reduced
average aggregation propensity relative to that of cat and
human (Table 3). We also predict the slightly increased
aggregation propensities of single or multiple mutations
of rat IAPP to the corresponding residues of human IAPP
[33]: R18H, L23F or V26I, as well as the results from
alanine-scanning-mutagenesis in a peptide encompassing
residues 22–27 [32] (Table 3). It has been found that a
substitution at position 20 (S20G) in the IAPP molecule
in a reduced subpopulation of Japanese people with type
II diabetes is associated with an earlier onset and more
severe form of disease [34]. In this case, our approach
does no predict an increased but a slightly reduced aggre-
gation propensity in the mutant, suggesting that the path-
ological symptoms in this variant may arise from non-
intrinsic factors. In fact, it has been suggested that the
accelerated aggregation of the S20G variant could be
related to structural reasons, resulting from a better pack-
ing of the turns connecting the β-sheets in the final proto-
filament structure [28] that cannot be predicted by the
present approach.
Several mechanisms have been proposed for IAPP fibril
formation in type II diabetes. One widely accepted mech-
anism is that in type II diabetes, increased production and
secretion of IAPP associated with increased demand for
insulin might result in accumulation and aggregation of
IAPP [35]. A second view considers that impaired process-
ing of the IAPP precursor molecule, proIAPP, by islet beta-
cells may lead to hypersecretion of unprocessed or par-
tially processed forms of proIAPP that may have a higher
tendency for aggregation compared to mature IAPP [35].
Our calculated average aggregation propensities for proI-
APP and processed IAPP support this view (Table 3).
α-Synuclein
Parkinson disease is the most common neurodegenerative
movement disorder and is pathologically characterized by
the presence of neuronal intracytoplasmatic deposits of
aggregated protein called Lewy bodies [36]. Lewy bodies
also occur in other cognitive disorders, globally known as
α-synucleinopathies. α-Synuclein is the major compo-
nent of the fibrils that form the Lewy bodies [36]. It is a
small (137 residues), natively unfolded, soluble, presyn-
aptic and highly conserved protein without a well-defined
Table 2: Comparison of predicted and experimental changes in 
aggregation for Aβ variants.
Mutation ∆AP* Observed 
aggregation‡
A21G -1.22 -
E22G +2.14 +
E22Q +0.44 +
F19P -5.09 -
F19T -4.73 -
I31L -1.07 -
I32L -1.07 -
I41G -5.76 -
I41A -4.52 -
I41L -1.075 -
A42G -1.21 -
A42V +3.95 +
∆1–4 +4.82 +
∆1–9 +21.86 +
∆40–42 -8.34 -
∆41–42 -4.26 -
V12E+V18E+M35T+I41N -18.96 -
F19S+L34P -9.18 -
* Change in average aggregation propensity
‡ Changes in aggregation determined experimentally.Page 5 of 15
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shown in Fig. 1. Several large aggregation-prone stretches
were predicted for the α-Synuclein sequence: region 1–18,
region 27–56 and specially region 61–94. Again, our pre-
dictions are in complete agreement with the experimental
data in the literature, as many studies suggest that the
central region of the protein, known as the non-Aβ com-
ponent of amyloid plaques (NAC, amino acids 61–95), is
the responsible for its aggregation process [37]. A peptide
comprising residues 68–78 of α-synuclein has been
shown to be the minimum fragment that, like α-synuclein
itself, forms amyloid fibrils and exhibits toxicity towards
cells in culture [38]. This fragment is included in the
region 62–80 which we predict as the sequence stretch
with the highest aggregation propensity. All the α-synucle-
inopathies are characterized by the accumulation of the
35 residues NAC fragment in the insoluble deposits [37].
Accordingly, this central region is predicted to have a
much higher average aggregation propensity than its solu-
ble precursor (∆AP = +38.47). The importance of this
hydrophobic stretch is further supported by its absence in
β-synuclein, a homologue of α-synuclein, with strongly
reduced propensity for fibril formation. It has been shown
that the deletion of amino acids 71–82 within the hydro-
phobic region abrogated the ability of human α-synuclein
to polymerize into fibrils [39]. Protease digestion studies
suggest that the core region of α-synuclein in the fibrils
could be longer, since a 7-kDa fragment (comprising resi-
dues 31–109) was shown to be protected from proteinase
K digestion [40]. This region contains the putative 12-res-
idue core domain, as well as the NAC region and includes
the second and third "hot spots" in our profile. A struc-
tural study on the organization of α-synuclein in the fibri-
lar state using site-directed spin labelling confirms that
the 34–101 residues region constitutes the core of the
fibrils forming a parallel in-register β-sheet structure
whereas the N terminus is structurally more heterogene-
ous and the C terminus (40 amino acids) is completely
unfolded [41].
Several α-Synuclein mutations appear associated with
familial early-onset Parkinson Disease: A30P, A53T and
E46K. All they map into our predicted second "hot spot".
The rates of fibril assembly of the E46K and A53T mutants
have been shown to be greater than those of the wild type
and A30P proteins [42]. We predict a similar average
aggregation propensity for the wild-type and the A30P
mutant and an slightly increased aggregation propensity
for the E46K mutant, but fail to foresee the effect of the
A53T mutation in promoting the formation of protofi-
brils. Obviously, other functional factors apart from the
intrinsic aggregation propensities can strongly influence
the aggregation tendency of unfolded polypeptide chains
within the cell. In fact the effects of α-synuclein mutations
have been associated either to an impaired degradation
inside lysosomes or to a reduced axonal transport of the
variants [43,44]. Both situations may result in increased
concentrations of the protein in certain regions of the neu-
ron that may favor the nucleation step of amyloid forma-
tion. According to this, α-synuclein gene triplication
identified in two independent families [45] has been
shown to accelerate the development of Parkinson dis-
ease. Thus, an increase in the amount of cellular α-synu-
clein appears to be important for the pathogenesis of
Parkinson disease, suggesting that the effects of the differ-
ent α-synuclein mutations on protein aggregation could
be quantitative, in terms of local concentration, rather
that qualitative. Thus, experimental deviations from the
theoretical predictions in natively unfolded proteins, in
addition to reflect limitations of the approach, might also
contain relevant information, prompting to find alterna-
tive structural, as in the case of amylin, or functional, as in
the case of α-synuclein, explanations for the observed
behavior.
Globular proteins
β2-Microglobulin
β2-Microglobulin-related amyloidosis is a common and
serious complication in patients on longterm hemodialy-
sis [46]. Intact β2-microglobulin is a major structural
component of the amyloid fibrils. β2-Microglobulin (β2-
m) is a small (99 residues) non-glycosilated protein with
an immunoglobulin-like fold consisting in two antiparal-
lel pleated β-sheets linked by a disulfide bond (Fig. 2). β2-
m has been shown to form amyloid fibrils in vitro under
different conditions, but in all cases β2-m populates
Table 3: Comparison of predicted and experimental changes in 
aggregation for IAPP variants, relative to the corresponding 
human IAPP sequence.
Variant ∆AP* Observed 
aggregation‡
(20–29) Cat -5.12 =
(20–29) Rat -16.46 -
(20–29) Hamster -32.73 -
R18H +0.94 +
L23F +1.70 +
V26I +0.42 +
R18H+L23F+V26I +3.06 +
(22–27) N22A +31.53 +
(22–27) F23A -42.96 -
(22–27) G24A +11.96 +
(22–27) I26A -44.5872 -
(22–27) L27A -33.99 -
S20G -1.09 +
ProIAPP +31.40 +?
* Change in average aggregation propensity
‡ Changes in aggregation determined experimentally.
? Not yet proved experimentally.Page 6 of 15
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BMC Structural Biology 2005, 5:18 http://www.biomedcentral.com/1472-6807/5/18Representation of the 3D structure of globular proteins related to disease.Figure 2
Representation of the 3D structure of globular proteins related to disease. The chain segments in which the predic-
tion and the experimental data coincide are colored in green. Those identified experimentally to be relevant for amyloid for-
mation but not predicted by the present approach are colored in blue. The regions predicted to be important for amyloid 
formation from which experimental data are not available or indicates that they are not involved in aggregation are shown in 
yellow.
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[47]. Under these conditions aggregation-prone regions, if
present, may promote and drive the aggregation event.
According to the analysis of the aggregation profile,
Aggregation profile of globular proteins related to disease.Figure 3
Aggregation profile of globular proteins related to disease. Minimal protein regions which have been proved experi-
mentally to be involved in aggregation are shown at the top of the plot as black bars. Regions in the core of the fibrils are 
shown as a grey bars (when information available).
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BMC Structural Biology 2005, 5:18 http://www.biomedcentral.com/1472-6807/5/18shown in Fig. 3, this protein displays four "hot spots"
encompassing residues 21–31, 56–69 and 79–85, and
87–91. These regions sharply coincide with four different
secondary structure elements in β2-m: β-strand 2, formed
by residues 21–31; β-strand 6, formed by residues 61–71;
β-strand 7; formed by residues 77–85 and β-strand 8,
formed by residues 86–95 (Fig. 2). In agreement with our
prediction a peptide comprising residues 21–41 has been
shown to form fibrils in isolation [48]. In addition, a N-
terminal fragment of this short peptide corresponding
exactly to our first "hot spot" [21-31] is also able to self-
assemble into fibrillar structures [49]. Interestingly
enough, the peptides 23–31 and 21–29 exhibited reduced
amyloidogenesis [49]. Thus, in this particular "hot spot"
the prediction delimits not only the overall region impor-
tant for aggregation but also its precise size. The amino
acid stretches 59–79 and its shorter version 59–71 which
overlap with the predicted second aggregation-prone
region of β2-m have been also shown to form fibrils [50].
The C-terminal fragment 72–99 of β2-m has been also
reported to form amyloid [51]. This 29 residues sequence
includes our third and fourth "hot spots" of aggregation.
The peptide 91–99 does not aggregate, indicating that the
last 9 residues of β2-m are not relevant for amyloidogen-
esis as predicted here [49]. The N-terminal region, for
which no aggregation propensity is predicted, is probably
not involved inthe aggregation process as evidenced by
the fact that the fragment 6–12 does not form fibrils [49].
This observation could be physiologically relevant since
the N-terminus of β2-m is truncated in 30% of the mole-
cules extracted from ex vivo fibrils [52].
In contrast to the human protein, mouse β2-m does not
form fibrils even at high concentration [53]. Based on this
observation a seven residues region corresponding to res-
idues 83–89 of human β2-m has been suggested to be par-
ticularly important for aggregation, since it corresponds to
the sequence with the highest divergence between both
species. This hypothesis has been tested experimentally,
since a heptapeptide bearing the human sequence is able
to self-assemble whereas the mouse version is not [53].
The complete mouse sequence is predicted to have a
strongly reduced aggregation propensity (∆AP = -47.86).
Overall, our predictions on the presence and location of
"hot spots" in β2-m are extremely accurate and overlap
with the experimentally found relevant regions (Fig. 2).
The observation that short peptides including the aggrega-
tion-prone regions described here form amyloids implies
that exposure of previously hidden short segments can
nucleate native proteins into the amyloid state and rein-
forces the hypothesis that fibril formation is sequence
specific.
One of the most urgent issues in the study of amyloid
fibrils is to reproduce the formation of fibrils under phys-
iological conditions. Recently, it has been found that low
concentrations of SDS around the critical micelle concen-
tration induce the extensive growth of β2-m amyloid
fibrils at physiological pH, probably through the SDS-
induced conformational change of β2-m monomers [54].
Contrarily to what was expected, the presence of low con-
centration of SDS had little effect on the stability of the
protein and did not promote global protein unfolding.
Our results strongly suggest that in β2-m the parts of the
molecule involved in aggregation are located in pre-
formed β-strands. Therefore, it is possible that local
unfolding events may allow anomalous intermolecular
interaction between this preformed elements leading to
the formation of an aggregated β-sheet structure. This
would explain the formation of amyloid deposits in
hemodyalisis patients in which no major unfolding of the
protein is expected to occur, as well as the effect of seeds,
which may have exposed aggregation prone β-strands, in
strongly accelerating the aggregation process of β2-m
under physiological conditions [55].
Lysozyme
Human lysozyme has been shown to form amyloid fibrils
in individuals suffering from nonneuropathic systemic
amyloidosis. The disease is always associated to point
mutations in the lysozyme gene and fibrils are deposited
widely in tissues [56]. The properties of two amyloidog-
enic lysozyme mutants (I56T and D67H) have been stud-
ied in detail and, when compared to those of the wild-
type protein, the mutants were found to have reduced
structural stability allowing unfolding to take place at
least partially at physiologically relevant temperatures
[57,58]. Thus, the formation of amyloid fibrils by human
lysozyme is likely to occur by the exposure of aggregation-
prone region previously hidden in the native structure.
The aggregation profile of lysozyme identifies three main
"hot spots" corresponding to residues 20–34, 50–62 and
73–104 (Fig. 3). The last large aggregation-prone region
includes several local maxima. The first "hot spot" maps
in helix B, the second in a β-hairpin of the β-domain and
the third includes helix C and a large flanking unstruc-
tured region at its N-terminus (Fig. 2). Although there is
no experimental characterization of amyloidogenic
regions in human lysozyme in the literature, this informa-
tion is available for the homologous hen lysozyme mole-
cule, which displays an almost identical 3D-structure. The
aggregation profile for the hen protein is very similar to
that of the human one despite the fact that our input con-
sists solely on the sequence and the identity between both
molecules is only of 40%. The equivalent "hot spots" in
hen lysozyme comprise residues 24–34, 50–62 and 76–
98. Experimental data suggests that the sequence of the β-
domain could be of particular relevance for lysozymePage 9 of 15
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Two peptides encompassing the β-domain of native
lysozyme displayed very different behavior: peptide 61–
82 appeared to be predominantly unstructured whereas
peptide 41–60 showed a high tendency to aggregate and
form extended β-sheet structures [59]. The first peptide
coincides with a region of very low aggregation propensity
in the aggregation profiles, whereas the second one covers
the region with the highest aggregation propensity in the
profile (residues 50–64). Interestingly enough, a peptide
spanning residues 49–64 has been shown to form fibrils
with the typical structure of amyloid showing that the first
residues of the 41–60 peptide are not relevant for aggrega-
tion, as predicted by our approach [60]. Another study has
reported that the major fragment incorporated in the core
of the fibril structure, as monitored using proteolysis,
encompasses the chain region 49–101 [61]. These lys-
ozyme fragments contain helix C and two of the three β-
strands of the β-domain of the native protein structure
and coincide with the limits of the second and third
regions in our predictions (Fig. 2 and 3). This observation
could be biologically relevant, since the β-domain and C-
helix of the human lysozyme have been shown to unfold
locally in the amyloidogenic variant D67H, which is asso-
ciated with the familial cases of systemic amyloidosis
linked to lysozyme deposition [58]. The C-helix is the α-
helix with the lowest helical propensity of hen lysozyme
according to both theoretical and peptide based studies
[59]. This low propensity might be related to the ability of
this region to be incorporated into the β-sheet rich fibril-
lar structured as have been reported for other protein sys-
tems [62]. Limited proteolysis of hen lysozyme renders
fragments 57–107 and 1–38/108–129 [61]. In the 1–38/
108–129 fragment the N-terminal and C-terminal ends of
the molecule are joined by a disulfide bond. Only frag-
ment 57–107, but not fragment 1–38/108–129, is able to
generate well defined amyloid [61]. Whereas the behavior
of the 57–107 fragment is expected from the analysis, one
should also expect the fragment 1–38 to have a high ten-
dency to aggregate. Two explanations are possible to
account for this discordance. First, it could occur that the
helical structure of this region prevents its conversion to β-
sheet conformation, since the A-helix displays the highest
helical propensity out of all lysozyme helices [59]. The
second possibility is that, being joined to the 108–129
region, predicted to have lower aggregation propensity,
steric hindrances limit self-assembly or alternatively the
average aggregation tendency of this peptide becomes
reduced. The analysis supports this last hypothesis report-
ing a decrease in aggregation propensity (∆AP = -5.34) in
the joined peptide respect the 1–38 peptide alone.
Transthyretin
Transthyretin (TTR) is a homotetramer of 127-amino acid
subunits. TTR is found in human plasma and cerebral spi-
nal fluid, the plasma form being the amyloidogenetic pre-
cursor. TTR constitutes the fibrillar protein found in
familial amyloidotic polyneuropathy (FAP) and senile
systemic amyloidosis (SSA) [63]. In the case of FAP, the
amyloid is associated with a point mutation in the TTR
gene. To date, 100 different TTR mutations have been
reported, many of which are amyloidogenic [64]. The
FAP-associated variants characterized thus far although
tetrameric, are destabilized [65]. This destabilization
allows tetramer dissociation to the amyloidogenic mono-
meric intermediate to occur under the influence of mild
denaturing denaturation conditions. More than 10 FAP-
related variants crystal structures have been solved, reveal-
ing that the tertiary and quaternary structures are essen-
tially identical to the wild type form [65]. This
observation suggests that the partial denaturation of TTR
is a requirement for amyloidogenesis. In this state, the
presence of "hot spots" of aggregation could play an espe-
cially important role in promoting/driving amyloid for-
mation. According to the analysis of the aggregation
profile shown in Fig. 3, the TTR monomer displays three
main "hot spots" encompassing residues 10–20, 23–33
and 105–118. Also in this case, aggregation-prone
sequences appear to be located in preformed β-sheet
structures: A β-strand (11–19), part of the B β-strand (28–
36) and G and beginning of H β-strands (104–123) (Fig.
3). Most of these secondary structure elements are
involved in the formation of the tetrameric structure: H
strands mediate the dimerization whereas A and G pro-
vide the contacts for the tetramerization of two preformed
dimmers. This explains the protective role played by the
TTR quaternary structure against aggregation, since it
hides or blocks most of the aggregation prone regions.
Dissociation of the tetramer has been reported as a prereq-
uisite for amyloidosis and according to our results might
be associated to the exposure of previously hidden amy-
loidogenic sequences. We detect several short peaks exhib-
iting high aggregation propensities in the central region
(63–94) of TTR. These result from the presence of almost
regularly placed residues with low aggregation propensity
(Asp, Glu, Arg, Lys, Gly) in this rather hydrophobic
sequence, which probably act as disrupters, significantly
lowering the aggregation tendency of this particular
region, a strategy suggested to be used by nature to avoid
edge-to-edge aggregation [66].
To date two different fragments of TTR have been shown
to form amyloid fibrils. The peptide 105–115 can be
assembled into homogeneous amyloid fibrils with favora-
ble spectroscopic properties [67]. This has allowed to
solve its fibrillar structure at high-resolution, showing that
it adopts an antiparallel extended beta-strand conforma-
tion in the amyloid fibrils [68]. This peptide coincides
with the region with the highest aggregation propensity in
the profile. Also in excellent agreement with the predic-Page 10 of 15
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reported to form amyloid fibrils [69]. No data are availa-
ble on the region 23–33 but the success of the present
method in predicting relevant regions in TTR suggests that
it is worth to characterize its in vitro aggregation
capabilities.
Prion protein
Misfolded isoforms of the naturally occurring prion pro-
tein (PrP) have been shown to be the causative agents in
many mammalian neurodegenerative disorders, includ-
ing Cruetzfeldt-Jakob disease (CJD) in human, scrapie in
sheep, and bovine spongiform encephalopathy in cows.
Prion infectivity is unique in that the pathogenic prion
form (PrPSc) is involved in the conversion of the endog-
enous conformation (PrPC) into transformed PrPSc. The
"protein-only" hypothesis [70] asserts further that no
extraneous agents are necessary to explain the unusual
behavior of prions. Prion diseases can have infectious,
familial, and sporadic origins. The basic infectious mech-
anism is thought to be a conformational change of the
normal prion protein (PrPC) into the pathogenic PrPSc
catalyzed by PrPSc itself.
The normal prion protein (PrPC) is a GPI-anchored glyco-
protein constitutively expressed on the surface of prima-
rily neuronal cells. It consists of two structurally different
parts; a C-terminal, globular part mainly α-helical in
nature (Fig. 2) and an unstructured, N-terminal part [71].
Misfolding of PrPC into PrPSc occurs posttranslationally
and results in increased β-sheet content and gain of pro-
tease-resistance. Fig. 3 shows the predicted "hot spots" in
the aggregation profile of the full-length human prion
protein. They are located at the N-terminus (1–32), in the
central region (105–146) and the C-terminus (208–252),
respectively.
The role of the detected aggregation-prone sequence at the
N-terminus is uncertain since it is out of the protease
resistant core of PrPSc. Little information exits about the
role of this region, although it appears to be unnecessary
both for prion transmission and aggregation. The pre-
dicted C-terminal "hot spot" includes almost all the C-ter-
minal α-helix, named C, from the globular domain (Fig.
2). Interestingly, some of the human mutations linked to
Creutzfeldt-Jakob disease occur in this region of the prion
protein and it has been related to the conversion of PrPC
into the toxic PrPSc. Moreover, some strains of PrP resist-
ant to conversion to PrPSc have been found to bear muta-
tions in helix C, and positions 214 and 218 have been
shown to modulate PrPSc formation [72]. It is also impor-
tant to note that the main structural differences between
prion proteins from different species have been found at
the end of helix C [71].
The central region of PrPC linking the unstructured N-ter-
minal part with the globular C-terminal domain is
believed to play a pivotal role in the PrPC conformational
changes. Extensive studies on the secondary structure and
fibrillogenic properties of synthetic peptides of PrP have
established that the continuous segment of the prion pro-
tein spanning residues 106–147, coincident with the sec-
ond "hot spot" predicted using our approach, is
important for the fibrillogenic properties of the protein
[73]. One of the synthetic peptides, that named PrP106-
126 within the central region of PrP and near the N-termi-
nal of the protease resistant core of PrPSc, shares many
properties with the infectious form as it readily forms
amyloid fibrils with a high β-sheet content, shows partial
proteinase K resistance and is neurotoxic in vivo [74]. The
neurotoxicity of PrP106-126 depends on the expression of
endogenous PrPC which makes PrP106-126 a relevant
model for PrPSc neurotoxicity [74]. Also another prion
derived peptide – PrP118-135 – has been found to cause
neuronal death via induction of apoptosis [75]. The
toxicity of PrP118-135 is, however, independent of
endogenous PrPC expression. Both peptides map in our
predicted central aggregation-prone region of PrPC.
Conclusion
Overall, the method described here appears as a useful
tool for the identification of protein regions that are espe-
cially relevant for protein aggregation and amyloidogene-
sis both in natively unfolded and properly folded globular
proteins (Table 4). The results provide support to the
hypothesis that short specific amino acid stretches can act
as triggers for the incorporation of polypeptides into amy-
loid structures. It is interesting to note that in those cases
in which structural information allows to delimitate the
region incorporated in the core of the fibrillar structure,
our predicted "hot spots" and those proved experimen-
tally are considerably shorter than the whole region, sug-
gesting that the role of "hot spots" is to act as specific
nucleation points from which the ordered fibrillar
structure is expanded.
Nature has provided globular proteins with a reasonable
conformational stability in the native state in which, as
proved here, aggregation-prone sequences are buried or
involved in intra-molecular interactions. This appears as a
very successful evolutive strategy to avoid aggregation,
since few proteins aggregate from their stable native con-
formation. Accordingly, amyloid-related mutations in
globular proteins usually result in destabilization of the
folded state allowing the exposure of previously hidden
"hot spots", as those reported here. This explains the
scarce success in predicting the effect of mutations in the
aggregation of globular proteins (data not shown),
whereas the prediction of fatal sequence changes in intrin-
sically unstructured proteins involved in disease is gener-Page 11 of 15
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explained in most cases by intrinsic factors, as they
directly result in changes on the average propensity of the
full polypeptide to aggregate.
Besides providing important clues about the mechanism
of protein aggregation, this study may be relevant for the
therapeutics of amyloid disease, since the identified "hot
spots" could be regarded as preferential targets to tackle
the deleterious disorders linked to protein deposition.
According to our results, different specific strategies
should be employed when designing methods to avoid
aggregation, depending on the disease being caused by
natively unfolded or by globular proteins. In Alzheimer,
type II diabetes and Parkinson diseases, shielding the
already exposed aggregation-prone regions in the
polypeptides by using small compounds or antibodies
appears as a promising approach, whereas compounds
that will stabilize the native conformation and avoid the
exposure of the deleterious "hot spots" will be more effec-
tive in the case of globular proteins. Additionally, when
gene therapy eventually comes to age, mutations that dis-
rupt aggregation-prone regions in unstructured polypep-
tides or those which over-stabilize the native state of
globular aggregation-prone proteins are expected to be
useful approaches to avoid protein deposition and melio-
rate neurodegenerative and systemic amyloidogenic
disorders.
Methods
Experimental determination of amino acids aggregation 
propensities
The CHC of Aβ42 peptide was chosen as a paradigmatic
aggregation-prone region for the calculation of the indi-
vidual effect of each natural amino acid on protein aggre-
gation. The specific effect on Aβ42's deposition promoted
by the 20 different natural amino acids when located in
the central position of this model "hot spot" were evalu-
ated. Briefly, the wild type Aβ42 gene and its 19 mutants
were inserted as a fusion protein upstream of the green
fluorescence protein (GFP) and expressed individually in
bacteria. In this system, the levels of GFP fluorescence in
the cells depend exclusively on the in vivo aggregation pro-
pensity of the Aβ42 variant [10,25], in such a way that
changes in aggregation propensities promoted by the dif-
ferent mutations can be easily monitored by measuring
the fluorescence emission of the cells expressing each par-
ticular variant and normalizing it relative to that emitted
by the cells bearing the wild type sequence. Three inde-
pendent clones were analyzed for each mutation and each
clone was analyzed at least by triplicate to generate con-
sistent data. To obtain the individual aggregation propen-
sities in Table 1, the change promoted by each amino acid
Table 4: List of the predicted "hot spots" in the different disease-linked polypeptides in this study and comparison with the available 
experimental data. Experimental "hot spots" refer to those protein regions shown to be involved in the aggregation process of the 
corresponding polypeptide. It is also noted if the predicted "hot spot" has been described as a structural element of the amyloid fibrils 
formed by the different peptides and proteins in the study.
Protein Predicted "Hot Spots" Experimental "Hot Spots" Regions in the fibrils
Amyloid-β-protein 16–21 + +
30–36 + +
38–42 + +
Islet amyloid polypeptide 12–18 + uncertain
22–28 + uncertain
1–18 No experimental data available uncertain
α-Synuclein 27–56 + uncertain
61–94 + +
β2-Microgobulin 21–31 + +
56–69 + +
79–85 + +
87–91 + +
Lysozyme (hen) 24–34 - -
50–62 + +
76–98 + +
Transthyretin 10–20 + +
23–33 No experimetal data available uncertain
105–118 + +
Prion Protein 1–32 No experimetal data available uncertain
105–146 + +
208–252 No experimetal data available uncertainPage 12 of 15
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of 20 amino acids.
Generation of aggregation profiles and identification of 
"hot spots"
Different experimental data suggest that the aggregation
of Aβ42 occurs from a mostly unfolded conformation in
which the CHC is exposed to solvent [76]. Assuming that
the individual intrinsic aggregation propensities obtained
analyzing this particular protein region will probably
apply for any unfolded sequence; an aggregation profile
was generated for every protein in this study through a
simple assignment of the values in Table 1 to each indi-
vidual residue in the corresponding sequences. Since "hot
spots" are clusters of consecutive residues, the sequence
was scanned by using a five residues sliding window. "Hot
spots" in the sequence were identified as those protein
regions at least five residues in length (the minimal size
shown to date to be required for a peptide to form amy-
loid fibrils similar to those formed by whole polypeptides
[77], in which the aggregation propensity is above the
average aggregation propensity of the complete sequence.
The average propensity of the polypeptide was calculated
as the sum of the aggregation propensities of its individual
amino acids divided by the number of residues.
Analysis of the effect of changes in the polypeptide 
sequence on aggregation
The concept of "hot spot" of aggregation implies that the
contribution of a particular residue in a protein sequence
on protein aggregation is somehow modulated by its
immediate neighbors. According to this, the effects of
mutation on protein aggregation can not be properly cal-
culated by a simple subtraction of the intrinsic aggrega-
tion propensities of the wild type and mutant residues.
Instead, to provide a more general description of the effect
of the change on the overall aggregation propensity, the
individual aggregation profiles for the wild type protein
and the different mutants are obtained and the differences
between the areas below the corresponding profiles are
calculated. The area between each profile was always nor-
malized by the number of residues in the considered spe-
cies to compare between the aggregation propensities of
the complete protein and fragments coming from proteol-
ysis, chemical synthesis or other processes. The difference
between normalized areas, multiplied by a 100 factor, was
designed as the change in average aggregation propensity
(∆AP). ∆AP will be positive if the mutation is predicted to
increase the aggregation propensity of the polypeptide
chain and negative if it is predicted to increase solubility.
Abbreviations
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